Hengrui Pharmaceutical Acetate Abitron Tablet (I) Approved clinically
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Drug Name: Acetate Abitone Tablet (I)Dosage Form: TabletApplication: Clinical TrialAcceptance Number: CXHL1900427Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, after examination, the acetate abitron tablets (I.) accepted on December 13, 2019 meet the relevant requirements of drug registration and agree to conduct clinical trials in accordance with the proposed programAbitron Research was developed by Johnson and Johnson, was first approved in the United States in April 2011, the product named Zytiga ®, has been listed in Canada, the European Union, Japan and other countries for saleIn 2015, Abitron was approved in China for a product called The ®according toIQVIA, Abitron's global sales in 2019 were approximately $323,277 million, u.Ssales were approximately $108.876 million and domestic sales were approximately $115.17 millionJuly 2019, Hengrui subsidiary Chengdu Shengdi Pharmaceutical Co., Ltddeclared the first imitation of acetate abit dragon tablets was approved for listingUp to now, there are another Zhengda Tianqing, Jiangxi Shanxiang two generic drugs approved for listing, and Qilu Pharmaceuticals, India's Reddy, Lianyungang Jerry three review and approvalsource: MinnetHengrui said that so far, the project has invested about 5.92 million yuan in research and development, will soon be launched in the end of the clinical trial of acetate abitron tablets (I).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
